BRIEF-Trillium Therapeutics' TTI-621 receives FDA clearance to proceed in clinical trial
August 17, 2016 at 07:26 AM EDT
* Trillium Therapeutics receives FDA clearance to proceed with TTI-621 in clinical trial targeting solid tumors and mycosis fungoides Source text for Eikon: Further company coverage:
